SK-GT-2 cell line

Adenocarcinoma of the Gastric fundus, poorly differentiated

SK-GT-2 was established from a primary adenocarcinoma of gastric fundus from a 72-year-old Hispanic male previously treated for squamous cell carcinoma with radiation therapy and radical neck dissection. Pathology of recurrence (1 year) demonstrated ulcerating poorly differentiated adenocarcinoma of the stomach invading spleen and epigastic fat (T4) with metastases to perisplenic and perigastric nodes (N1). SK-GT-2 was found to be tumorigenic in athymic nu/nu mice. The Y chromosome could not be detected in this cell line by short tandem repeat (STR)-PCR analysis when tested at ECACC. It is a known phenomenon that due to the increased genetic instability of cancer cell lines the Y chromosome can be rearranged or lost resulting in lack of detection. The cell line is identical to the source provided by the depositor based on the STR-PCR analysis.

STR-PCR Data: Amelogenin: X
CSF1PO: 10
D13S317: 12,13
D16S539: 11,12
D5S818: 10
D7S820: 9,10
THO1: 8,9
TPOX: 9,12
vWA: 15,18

RPMI-1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS)

Split sub-confluent cultures (70-80%) 1:4 to 1:10 i.e. seeding at 1-3 x 10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO₂; 37°C. Population doubling approx 44hrs.

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.